These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27016395)

  • 1. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.
    Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S
    J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery.
    Wagner L; Wolf R; Zeitschel U; Rossner S; Petersén Å; Leavitt BR; Kästner F; Rothermundt M; Gärtner UT; Gündel D; Schlenzig D; Frerker N; Schade J; Manhart S; Rahfeld JU; Demuth HU; von Hörsten S
    J Neurochem; 2015 Dec; 135(5):1019-37. PubMed ID: 26442809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel neuropeptide Y processing in human cerebrospinal fluid from depressed patients.
    Ekman R; Juhasz P; Heilig M; Agren H; Costello CE
    Peptides; 1996; 17(7):1107-11. PubMed ID: 8959743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease.
    Decressac M; Wright B; Tyers P; Gaillard A; Barker RA
    Exp Neurol; 2010 Nov; 226(1):24-32. PubMed ID: 20673761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Nilsson CL; Brinkmalm A; Minthon L; Blennow K; Ekman R
    Peptides; 2001 Dec; 22(12):2105-12. PubMed ID: 11786197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C-terminal flanking peptide of neuropeptide Y (NPY) is not essential for seizure-suppressant actions of prepro-NPY overexpression in male rats.
    Soud K; Jørgensen SH; Woldbye DPD; Sørensen AT
    J Neurosci Res; 2019 Mar; 97(3):362-372. PubMed ID: 30367522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry.
    Nilsson C; Westman A; Blennow K; Ekman R
    Peptides; 1998; 19(7):1137-46. PubMed ID: 9786162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease.
    Barschke P; Abu-Rumeileh S; Al Shweiki MHDR; Barba L; Paolini Paoletti F; Oeckl P; Steinacker P; Halbgebauer S; Gaetani L; Lewerenz J; Ludolph AC; Landwehrmeyer GB; Parnetti L; Otto M
    J Neurol; 2022 Sep; 269(9):5136-5143. PubMed ID: 35737109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.
    Rose JB; Crews L; Rockenstein E; Adame A; Mante M; Hersh LB; Gage FH; Spencer B; Potkar R; Marr RA; Masliah E
    J Neurosci; 2009 Jan; 29(4):1115-25. PubMed ID: 19176820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive glycome profiling of Huntington's disease transgenic mice.
    Gizaw ST; Koda T; Amano M; Kamimura K; Ohashi T; Hinou H; Nishimura S
    Biochim Biophys Acta; 2015 Sep; 1850(9):1704-18. PubMed ID: 25907331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.
    Vinther-Jensen T; Simonsen AH; Budtz-Jørgensen E; Hjermind LE; Nielsen JE
    Eur J Neurol; 2015 Oct; 22(10):1378-84. PubMed ID: 26073975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.
    Rodrigues FB; Byrne L; McColgan P; Robertson N; Tabrizi SJ; Leavitt BR; Zetterberg H; Wild EJ
    J Neurochem; 2016 Oct; 139(1):22-5. PubMed ID: 27344050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Levels of Prodynorphin-Derived Peptides are Decreased in Huntington's Disease.
    Al Shweiki MR; Oeckl P; Pachollek A; Steinacker P; Barschke P; Halbgebauer S; Anderl-Straub S; Lewerenz J; Ludolph AC; Bernhard Landwehrmeyer G; Otto M
    Mov Disord; 2021 Feb; 36(2):492-497. PubMed ID: 33006791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropeptide Y - an early biomarker for cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
    Schebesch KM; Brawanski A; Bele S; Schödel P; Herbst A; Bründl E; Kagerbauer SM; Martin J; Lohmeier A; Stoerr EM; Proescholdt M
    Neurol Res; 2013 Dec; 35(10):1038-43. PubMed ID: 23915659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential feeding responses evoked in the rat by NPY and NPY1-27 injected intracerebroventricularly.
    Paez X; Nyce JW; Myers RD
    Pharmacol Biochem Behav; 1991 Feb; 38(2):379-84. PubMed ID: 2057507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease.
    Lowe AJ; Sjödin S; Rodrigues FB; Byrne LM; Blennow K; Tortelli R; Zetterberg H; Wild EJ
    PLoS One; 2020; 15(8):e0233820. PubMed ID: 32804976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease cerebrospinal fluid seeds aggregation of mutant huntingtin.
    Tan Z; Dai W; van Erp TG; Overman J; Demuro A; Digman MA; Hatami A; Albay R; Sontag EM; Potkin KT; Ling S; Macciardi F; Bunney WE; Long JD; Paulsen JS; Ringman JM; Parker I; Glabe C; Thompson LM; Chiu W; Potkin SG
    Mol Psychiatry; 2015 Nov; 20(11):1286-93. PubMed ID: 26100538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropeptide Y1 receptor antagonist but not neuropeptide Y itself increased bone mineral density when locally injected with hyaluronic acid in male Wistar rats.
    Çevik MÖ; Korkusuz P; Korkusuz F
    Turk J Med Sci; 2020 Aug; 50(5):1454-1460. PubMed ID: 32490636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortical peptide changes in Huntington's disease may be independent of striatal degeneration.
    Mazurek MF; Garside S; Beal MF
    Ann Neurol; 1997 Apr; 41(4):540-7. PubMed ID: 9124812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.